Lupin Launches World's First Triple Combination Drug for COPD Treatment in India

23 Nov 2023 , 02:52 PM

Lupin Limited launches world’s first fixed-dose triple combination drug, Vilfuro-G, for COPD treatment in India. Approval granted by the Drug Controller General of India for the dry powder inhaler (DPI) product.

Vilfuro-G is the only FDC combining vilanterol, fluticasone furoate, and glycopyrronium bromide for moderate to severe COPD. The product addresses the long-term management of COPD, affecting over 37 million individuals in India.

Lupin’s Q2 consolidated net profit rose 3.77-fold YoY to Rs 489.6 crore, with revenue at Rs 5038.56 crore, up 24.9% from the previous year.

For feedback and suggestions, write to us at [e-mail]